Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2017 · second_quarter · 2A
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Source: Senate LDA
Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Cancer Drug Parity Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Cancer Drug Parity Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Cancer Drug Parity Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Protecting Seniors Access to Medicare Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Seniors Access to Medicare Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Medicare from Executive Action Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Medicare from Executive Action Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Seniors' Access to Medicare Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Seniors' Access to Medicare Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.4857, S.2980); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R.4187)
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Cancer Drug Coverage Parity Act (H.R.1801, S.1879).
Health Savings Account Expansion Act of 2016
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.4857, S.2980); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R.4187)
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Cancer Drug Coverage Parity Act of 2013
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Cancer Drug Coverage Parity Act (H.R.1801, S.1879).
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.4857, S.2980); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R.4187)
Cancer Drug Coverage Parity Act of 2013
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152); Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Cancer Drug Coverage Parity Act of 2013
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879). Issues related to the Veterans Access to Care Act (H.R. 4810, S. 2450).
Cancer Drug Coverage Parity Act of 2013
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Cancer Drug Coverage Parity Act of 2013
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient proposed rule (no specific bills). Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) H.R. 4187
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient issues (H.R.4857). Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152); Issues related to the Medicare hospital outpatient issues (H.R. 4857, S. 2980); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient issues (H.R.4857). Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Veteran Access to Care Act of 2014
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879). Issues related to the Veterans Access to Care Act (H.R. 4810, S. 2450).
Ensuring Equal Access to Treatments Act of 2014
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152); Issues related to the Medicare hospital outpatient issues (H.R. 4857, S. 2980); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Ensuring Equal Access to Treatments Act of 2014
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient issues (H.R.4857). Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Ensuring Equal Access to Treatments Act of 2014
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient issues (H.R.4857). Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Cancer Treatment Parity Act of 2013
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Cancer Treatment Parity Act of 2013
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Cancer Treatment Parity Act of 2013
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879). Issues related to the Veterans Access to Care Act (H.R. 4810, S. 2450).
Cancer Treatment Parity Act of 2013
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152); Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Veterans' Access to Care through Choice, Accountability, and Transparency Act of 2014
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879). Issues related to the Veterans Access to Care Act (H.R. 4810, S. 2450).
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2017 · second_quarter · Q2
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2017 · first_quarter · Q1
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues.
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2016 · fourth_quarter · Q4
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment.
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2016 · third_quarter · Q3
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2016 · second_quarter · Q2
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2016 · first_quarter · Q1
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2015 · fourth_quarter · Q4
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2015 · third_quarter · Q3
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2015 · second_quarter · Q2
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2015 · first_quarter · Q1
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.4857, S.2980); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R.4187)
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Cancer Drug Coverage Parity Act (H.R.1801, S.1879).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2014 · fourth_quarter · Q4
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152); Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152); Issues related to the Medicare hospital outpatient issues (H.R. 4857, S. 2980); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2014 · third_quarter · Q3
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient issues (H.R.4857). Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2014 · second_quarter · Q2
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient issues (H.R.4857). Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879). Issues related to the Veterans Access to Care Act (H.R. 4810, S. 2450).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2014 · first_quarter · Q1
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient proposed rule (no specific bills). Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) H.R. 4187
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2013 · fourth_quarter · Q4
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, no specific Senate bill).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient proposed rule (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE